The content on this site is intended for healthcare professionals only
Judy Knudson PA-C speaks to ecancer at the online ONS 2020 meeting about the use of PARP inhibitors in oncology.
She explains the perspective from a palliative care nurse, which normally only sees the patients for whom PARP inhibitors did not work.
She does explain the benefits to the patient that arise from oral treatments, but sometimes these benefits come at a financial or toxic cost.
She is overall extremely excited about the prospects of these medicines.
Ms Knudson then explains the impact of the COVID-19 pandemic on palliative care including telecommunication, video calling, and healthcare professional self-care.
This programme has been supported by an unrestricted educational grant from Pfizer.
Gaza's cancer patients: Navigating the dual struggle of illness and war
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Durable responses in aRCC, how do we optimise treatment?
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients
